Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibodies - Aridis Pharmaceuticals

Drug Profile

Research programme: monoclonal antibodies - Aridis Pharmaceuticals

Alternative Names: Anti-infective mAbs - Kenta Biotech/Aridis; AR 401 (anti-AB mAb) - Aridis; AR-401; KBAB 401; KBPA 102; KBPA 103; KBPA 104; KBSA 201; KBSA 302

Latest Information Update: 28 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kenta Biotech
  • Developer Aridis Pharmaceuticals; Kenta Biotech
  • Class Antibacterials; Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acinetobacter infections
  • Discontinued Pseudomonal infections

Most Recent Events

  • 24 Sep 2018 Aridis Pharmaceuticals has patent protection for AR 401 in Australia, China, and Europe
  • 24 Sep 2018 Aridis Pharmaceuticals has patent pending for for AR 401 in China, Japan, and Canada
  • 24 Sep 2018 Aridis Pharmaceuticals receives patent allowance for AR 401 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top